RAPT Therapeutics Q4 EPS $(0.80) Beats $(0.86) Estimate, Cash Balance of $158.9M as of December 31, 2023
Portfolio Pulse from Benzinga Newsdesk
RAPT Therapeutics reported Q4 EPS of $(0.80), surpassing the $(0.86) estimate, marking a 25% increase in losses from the previous year. The company's cash balance stood at $158.9M as of December 31, 2023.
March 07, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RAPT Therapeutics exceeded Q4 EPS estimates but reported a 25% increase in losses compared to last year, with a cash balance of $158.9M.
While RAPT Therapeutics beating EPS estimates is positive, the 25% increase in losses year-over-year could concern investors. The substantial cash balance may provide some reassurance about the company's financial health in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100